Interestingly, the researchers also found that by blocking these THBS1 with antibodies the damage could be reversed. These ...

Viruses like the one that causes COVID-19 constantly mutate, rendering many antibody treatments ineffective. A Stanford-led ...

A Stanford-led team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is ...

This is useful when designing new therapies that enable another type of antibody to get a foothold and attach to the receptor ...

Perspective, Therapeutics (CATX) announced that the first patient was dosed in a new cohort of a Phase 1/2a trial evaluating the safety of ...

India-based Sun Pharmaceutical Industries Limited agreed to acquire U.S.-based immunotherapy and targeted oncology company ...

The Food and Drug Administration (FDA) has approved Tevimbra® (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the ...

They found that all the antibodies block the receptors the virus uses to bind to host cells and spread infection but with varying efficacy, suggesting the evolution of an equilibrium whereby the ...

EBV antibodies trigger MS by attacking brain proteins. Genetic factors worsen risk. Breakthrough insights for treatment.

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...